Aegis Therapeutics To Present At The "13th Annual Drug Delivery Summit" In New Brunswick, NJ, September 22-23, 2008

Main Category: Conferences
Article Date: 24 Aug 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: "New Technologies Expanding Practical Clinical Uses of Peptides, Proteins, and Other Macromolecular Therapeutics" at Insight's "13th Annual Drug Delivery Summit." The conference will be held on September 22-23, 2008 at the Hyatt Regency, New Brunswick, NJ. Dr. Edward T. Maggio, President and CEO of Aegis, will present studies on the application of Aegis' Intravail® non-invasive drug delivery technology, and Aegis' ProTek® protein stabilization technology to specific peptide, protein, and small molecule therapeutics.

Information about the conference may be obtained from the following website.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

Aegis Therapeutics